NCT00199342View on ClinicalTrials.gov

A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

October 31, 2005

Conditions
Stage IV Melanoma
Interventions
DRUG

KW-2871

potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma

Trial Locations (2)

22612

H. Lee Moffitt Cancer Center, Tampa

35294

Comprehensive Cancer Center- University of Alabama at Birmingham, Birmingham

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.
All Listed Sponsors
lead

Kyowa Kirin, Inc.

INDUSTRY